gene

IDE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about IDE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

254Connections
30Hypotheses
0Analyses
50Outgoing
50Incoming
13Experiments
0Debates

Summary

IDE is a gene implicated in neurodegeneration research. Key relationships include: activates, regulates, associated with. Associated with Als, Alzheimer, Carcinoma. Connected to 35 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolIDE
AliasesPage for IDE Gene
Chromosome10q23.33
Protein TypeProtease
FunctionPeptide hydrolysis, amyloid clearance
Molecular Weight110 kDa
Amino Acids1019 aa
PathwaysOxidative Stress
NCBI Gene ID3416
GeneCardsIDE
Human Protein AtlasIDE
Amyloid-beta degradationPrimary enzyme responsible for clearing Abeta in the brain
Insulin metabolismRegulates insulin signaling through peptide degradation
ProteostasisMaintains cellular protein quality control
Disease associationsAlzheimer's disease, Parkinson's disease, Type 2 diabetes
Associated DiseasesAls, Alzheimer, Alzheimer's disease, Diabetes, Insulin Resistance
Known Drugs/Compoundsmetformin
InteractionsACE, ACE2, AD, ADAM10, AKT, ALZHEIMER
KG Connections254 knowledge graph edges
DatabasesGeneCardsUniProtHPASTRING

Wiki Pages (6)

Knowledge base pages for this entity

Canonical Page

IDE Gene - Insulin-Degrading Enzyme

gene · 888 words

CIDEA — Cell Death-Inducing DFFA-Like Effector A

gene · 1992 words

CIDEC Gene

gene · 1894 words

Insulin-Degrading Enzyme (IDE)

protein · 1789 words

Rifaximin SSD in Dementia Trial (RIDE)

clinical · 1156 words

CIDEB — Cell Death-Inducing DFFA-Like Effector B

gene · 1125 words

Pathway Diagram

graph TD
    IDE["IDE"]
    Fibrosis{"Fibrosis"}
    IDE -->|"activates"| Fibrosis
    Hepatitis{"Hepatitis"}
    IDE -->|"activates"| Hepatitis
    Carcinoma{"Carcinoma"}
    IDE -->|"activates"| Carcinoma
    Cirrhosis{"Cirrhosis"}
    IDE -->|"activates"| Cirrhosis
    Inflammation{"Inflammation"}
    IDE -->|"activates"| Inflammation
    Ms{"Ms"}
    IDE -->|"activates"| Ms
    Diabetes{"Diabetes"}
    IDE -->|"associated with"| Diabetes
    Alzheimer{"Alzheimer"}
    IDE -->|"associated with"| Alzheimer
    CD36["CD36"]
    IDE -->|"activates"| CD36
    Er_Stress(["Er Stress"])
    IDE -->|"activates"| Er_Stress
    Unfolded_Protein_Response(["Unfolded Protein Response"])
    IDE -->|"activates"| Unfolded_Protein_Response
    Oxidative_Stress(["Oxidative Stress"])
    IDE -->|"activates"| Oxidative_Stress
    CD36 -->|"activates"| IDE
    INFLAMMATION["INFLAMMATION"]
    INFLAMMATION -->|"activates"| IDE
    OXIDATIVE_STRESS["OXIDATIVE STRESS"]
    OXIDATIVE_STRESS -->|"activates"| IDE
    style IDE fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (155)

TargetRelationTypeStr
Alzheimerassociated_withdisease0.85
AMYLOID BETAdegradesprotein0.80
STINGinhibitsgene0.70
PSEN1expressesgene0.70
NEPdegradesgene0.70

Incoming (99)

SourceRelationTypeStr
INSULINupregulatesprotein0.80
APPregulatesgene0.70
BACE1expressesgene0.70
BDNFexpressesgene0.70
CREBregulatesgene0.70

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Palmitoylethanolamide-Based Endocannabinoid Therapy 0.919 - Blood-brain barrier tight junction disru
Real-time gamma-guided transcranial focused ultrasound targe 0.827 Alzheimer's disease Circuit-level neural dynamics in neurode
CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Wind 0.801 neuroimmunology TREM2 in Alzheimer's Disease: Mechanisms
Competitive APOE4 Domain Stabilization Peptides 0.784 neurodegeneration APOE4 structural biology and therapeutic
Integrated Biomarker Panel for Therapeutic Window Identifica 0.784 neurodegeneration What are the precise temporal dynamics o
miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy 0.741 molecular biology Is APOE4's reduced lipid binding pathoge
Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in 0.735 Alzheimer's disease TREM2 agonism vs antagonism in DAM micro
SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduct 0.732 neurodegeneration How do sphingomyelin/ceramide ratios spe
ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2 0.725 lipidomics Lipid metabolism dysregulation in Alzhei
Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency 0.720 neurodegeneration APOE4 targeting in neurodegeneration
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides 0.718 neurodegeneration Blood-brain barrier transport mechanisms
H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properti 0.698 neurodegeneration How do pathological stress granules tran
Ganglioside Rebalancing Therapy 0.690 neurodegeneration Lipid raft composition changes in synapt
GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis B 0.680 - Ferroptosis in ALS and motor neuron dise
Axonal Transport Defect: C9orf72 hexanucleotide expansion im 0.660 neurodegeneration What are the neuron-specific effects of
Loss of Homeostatic Epigenetic Identity Reprograms Microglia 0.650 neurodegeneration What molecular mechanisms drive microgli
DNMT1-Targeting Antisense Oligonucleotide Reset 0.648 neurodegeneration Epigenetic clocks and biological aging i
Parthenolide reduces tonic ADORA2A signaling by lowering inf 0.640 neuropharmacology How does parthenolide specifically modul
Myelin Sulfatide Restoration 0.623 neurodegeneration Gene expression changes in aging mouse b
Dual-Phase Medium-Chain Triglyceride Intervention 0.622 neurodegeneration How do astrocyte-neuron metabolic intera
CSF Biomarker-Guided ABCA7 Therapeutic Dosing 0.619 neurodegeneration Why does the V1613M variant reduce amylo
Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar 0.613 neurodegeneration CRISPR-based therapeutic approaches for
C1q effector output is determined more by binding partner id 0.610 neurodegeneration Does C1q function differ based on subcel
Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therap 0.599 neurodegeneration Which cell types show the most significa
Ganglioside-rich extracellular vesicles preserve alpha-synuc 0.582 neurodegeneration Which specific CSF molecular components
Spatial Transcriptome-Guided Precision Cell Therapy 0.578 neurodegeneration Cell type vulnerability in Alzheimer's D
NAD+/SARM1 Axis Provides Metabolic Feedback Coupling Mitopha 0.578 neurodegeneration How do different organelle-specific auto
H63D HFE Genotype-Guided Iron Chelation Therapy for Subset-S 0.550 - Ferroptosis in ALS and motor neuron dise
Digital Twin-Guided Metabolic Reprogramming 0.550 neurodegeneration Digital biomarkers and AI-driven early d
GPP Repeat Peptide-Fc Fusion for Enhanced Brain Penetration 0.550 neurodegeneration Blood-brain barrier antibody transport m

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (13)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
GWAS of plasma NfL in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma pTau217 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort clinical Alzheimer's disease 0.950 0.00 Swedish community-based adults proposed N/A
GWAS of plasma pTau181 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma GFAP in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on clinical Alzheimer's disease 0.950 0.00 recently menopausal women with proposed N/A
Autophagy receptor identification for stress granule elimination exploratory neurodegenerative diseases 0.900 0.00 cultured cells under arsenite proposed N/A
GWAS of composite biomarker score exploratory Alzheimer's disease 0.900 0.00 human patients - East Asian co proposed N/A
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
Chi3l1 deletion effects on baseline glial activation in mice validation baseline neuroinflammation 0.900 0.00 Chi3l1 knockout mice proposed N/A
CHI3L1 variant association with AD progression in human patients exploratory Alzheimer's disease 0.850 0.00 human patients proposed N/A
APOE4 association with TDP-43 pathology in AD exploratory Alzheimer's disease 0.750 0.00 human patients proposed N/A
s:** - Biochemical binding assays measuring PROTAC selectivity for APO falsification Neurodegeneration 0.400 0.50 cell_line proposed $100,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] Banik SM, Pedram K, Wisnovsky S, Ahn G, Nature 2020 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomy [PMID:41692468] ["Hsu-Heng Lin", "Hui-An Chen", "Shyh-Je Molecular genetics & genom 2026 0
Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] ["Aron Park", "Baeki E Kang", "Eun-Ju Ji Genes & genomics 2026 0
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] ["Barger S", "Moerman-Herzog A"] Frontiers in molecular neurosc 2026 0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha Frontiers in bioscience (Landm 2026 0
Mammalian lipophagy: process and function. [PMID:41681129] Zhao R, Dai E, Kang R, Liu J, Klionsky D Autophagy 2026 0
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] ["Wang M", "Niu D", "Zhang Q", "Tang Y", International journal of biolo 2026 0
Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: [PMID:41921464] Catino F, Castellana F, Zupo R, Giannocc Artificial intelligence in med 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis [PMID:40771159] Padilla CM, Lafyatis R, Gibson KF, Morse Arthritis Care Res (Hoboken) 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
A multi-dimensional bioinformatic dissection of the molecular mechanisms in high [PMID:41191606] Yu X MD, Lei J MSc, Du X MSc, He Y MSc, Int J Surg 2026 0
Plasma metabolites may inhibit childhood obesity by regulating ferroptosis throu [PMID:41249848] Wang JG, Pan XH, Li Y Int J Obes (Lond) 2026 0
Multi-omics analysis identifies SMPD1 as a key contributor in sphingolipid pathw [PMID:41428198] Park A, Kang BE, Jin EJ, Kim HJ, Lee CW Genes Genomics 2026 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning IDE in their description or question text

miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy

Score: 0.741 · molecular biology · 2026-04-16

## Mechanistic Overview miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy starts from the claim that modulating

Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Anta

Score: 0.735 · Alzheimer's disease · 2026-04-04

## Mechanistic Overview Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Ph

SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regula

Score: 0.732 · neurodegeneration · 2026-04-16

**Molecular Mechanism and Rationale** The molecular foundation for SMPD1 inhibition in Alzheimer's disease centers on t

ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2 to Protect Synaptic

Score: 0.725 · lipidomics · 2026-04-25

ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2 to Protect Synaptic Membranes from Aβ-Induced Rigidificatio

Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency

Score: 0.720 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The apolipoprotein E (APOE) gene encodes a 299-amino acid glycoprotein that serve

Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides

Score: 0.718 · neurodegeneration · 2026-04-02

## Mechanistic Overview Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides starts from the claim that modulating

H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties

Score: 0.698 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The pathogenic mechanism underlying C9orf72-associated amyotrophic lateral sclero

Ganglioside Rebalancing Therapy

Score: 0.690 · neurodegeneration · 2026-04-02

## Mechanistic Overview Ganglioside Rebalancing Therapy starts from the claim that modulating ST3GAL2/ST8SIA1 within the

GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade

Score: 0.680 · unknown disease · 2026-04-16

## Mechanistic Overview GPX4 Selenopeptide Mimetics as Neuroprotective Ferroptosis Blockade starts from the claim that m

Axonal Transport Defect: C9orf72 hexanucleotide expansion impairs retrograde aut

Score: 0.660 · neurodegeneration · 2026-04-21

## Mechanistic Overview Axonal Transport Defect: C9orf72 hexanucleotide expansion impairs retrograde autophagosome trans

Loss of Homeostatic Epigenetic Identity Reprograms Microglia to Dystrophic State

Score: 0.650 · neurodegeneration · 2026-04-22

## Mechanistic Overview Loss of Homeostatic Epigenetic Identity Reprograms Microglia to Dystrophic State starts from the

DNMT1-Targeting Antisense Oligonucleotide Reset

Score: 0.648 · neurodegeneration · 2026-04-02

## Mechanistic Overview DNMT1-Targeting Antisense Oligonucleotide Reset starts from the claim that modulating DNMT1 with

Parthenolide reduces tonic ADORA2A signaling by lowering inflammatory extracellu

Score: 0.640 · neuropharmacology · 2026-04-25

NF-kB suppression in glia decreases ectonucleotidase and cytokine programs that sustain extracellular adenosine, indirec

Myelin Sulfatide Restoration

Score: 0.623 · neurodegeneration · 2026-04-04

## Mechanistic Overview Myelin Sulfatide Restoration starts from the claim that modulating GAL3ST1 within the disease co

Dual-Phase Medium-Chain Triglyceride Intervention

Score: 0.622 · neurodegeneration · 2026-04-12

**Molecular Mechanism and Rationale** The dual-phase medium-chain triglyceride (MCT) intervention targets key enzymes i